Best Life Sciences Companies in Gyeonggi do, South Korea
The 73 best Life Sciences companies in Gyeonggi do, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Rznomics.
Our analysis of 50 Life Sciences companies
$4.0b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Gyeonggi do
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Rznomics Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology 57Growth top 15%Patents top 28%Moat top 32%Innovation top 33% All 9 signals ▾Growthtop 15% Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 38% Talentbottom 49% Marketbottom 44% Globalbottom 42% Techbottom 22% Growth: Web rank 50,000,000 → 5,000,000 YoY Patents: 61 patents matched (strict assignee match) · 51 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $49M | 48 mo ago | Public | Seong-Wook Lee Founder & CEO | 2017 | PHPYouTubeNginx+6 | 61 patents Patents concentrated in chemistry & materials | — |
| 2 | MedInTech Developer of medical device technologies 76Patents top 22%Innovation top 25%Funding top 42%AI top 45% All 6 signals ▾Patentstop 22% Innovationtop 25% Fundingtop 42% AItop 45% Globaltop 48% Talentbottom 49% Patents: 113 patents matched (strict assignee match) · 111 filings since 2022 vs 2 in 2017-21 Innovation: 113 patents (top 25% of patent-holders) · 111 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $21M | 25 mo ago | Series B | Chiwon Lee CEO | 2020 | — | 113 patents Patents concentrated in health & consumer products | — |
| 3 | Pharos iBio Provider of therapeutics for oncology and rare disease | $16M | 60 mo ago | Public | Jeonghyeok Yoon CEO | 2016 | — | 36 patents Small-molecule kinase inhibitors targeting KIT/PDGFRA for oncology therapeutics | — |
| 4 | Txinno Developer of therapeutics for the treatment of cancer | $8M | 58 mo ago | Series A | Chan-Sun Park CEO & Co-Founder | 2020 | — | — | — |
| 5 | CrossPoint Therapeutics Developer of immunotherapies for cancer treatment 27Moat top 45%Patents top 47%Funding bottom 46%Talent bottom 45% All 6 signals ▾Moattop 45% Patentstop 47% Fundingbottom 46% Talentbottom 45% Innovationbottom 40% Globalbottom 31% Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents Patents: 5 patents matched (strict assignee match) · 5 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | Seed | Tae-Erk Kim Co-Founder & CEO | 2022 | — | 5 patents Patents concentrated in chemistry & materials | — |
| 6 | NB POSTECH Developer of rapid diagnostic test kits for COVID-19 | — | 30 mo ago | Seed | Joon Park Founder & CEO | 2008 | — | 44 patents Laser welding cooling systems, meta-holographic displays, waterproof coatings, and smart infrastructure robotics. | — |
| 7 | Medihub Manufacturer of anaesthetic injection system | — | 96 mo ago | Seed | Maro Yeom CEO | 2013 | — | 40 patents Patents concentrated in health & consumer products | — |
| 8 | OliPass Developer of PNA Therapeutics for the treatment of multiple diseases | — | 96 mo ago | Public | — | 2006 | JavaSwiperjQuery UI+5 | 127 patents Antisense and peptide nucleic acid therapeutics for gene‑silencing drug targets | — |
Top 9 Life Sciences companies in Gyeonggi do
#1
Seed · Hwaseong, Gyeonggi do · founded 2022$2.4Mraised▾
Developer of immunotherapies for cancer treatment. It offers Stealth-Body technology and Fc inert antibody platform for development of antibody therapies which include CPP-001 for Protein delivery, CPS-001 for Small molecule delivery, and CPR-001 for Gene delivery to cure cancer.
- Mar 2026Seed$2.4M
#2
Series B · Hanam si, Gyeonggi do · founded 2020$21.2Mraised▾
Developer of medical device technologies. The company focuses on research and development, bringing innovative medical devices to market. Its expertise lies in the creation and enhancement of medical technology, contributing to advancements in healthcare. It feature anomaly detection and lesion identification software based on artificial intelligence, aimed at enhancing diagnostic accuracy and eliminate misdiagnosis.
- May 2024Series B$14.6M
- Feb 2022Series A$6.7M
#3
Public · Yongin si, Gyeonggi do · founded 2017 · 39 employees$48.7Mraised▾
Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology. It has developed gene therapy products for the treatment of various cancers, degenerative diseases, hereditary diseases of liver cancer, and others. It's lead products RZ001that helps in treating cancer diseases, RZOO2, RZ003 helps in the treatment of Alzheimer's diseases.
- Jun 2022Series C$29.8M
- Sep 2019Series A$10M
#4
Public · Anyang, Gyeonggi do · founded 2016 · 22 employees$15.9Mraised▾
Provider of therapeutics for oncology and rare disease. The company's drug candidates include PHI-101-001 for acute myeloid leukemia, PHI-101-002 for ovarian cancer, PHI-101-003 for metastatic triple-negative breast cancer, PHI-401 for lung adenocarcinoma with ALK mutation, and others.
- Jun 2021Series C$15.9M
#5
Series A · Yongin si, Gyeonggi do · founded 2020 · 25 employees$8.5Mraised▾
Developer of therapeutics for the treatment of cancer. The company develops therapeutic agents focusing on the two characteristics, "small-molecule compound targeting innate immunity" in immunotherapy and "RAS mutated anti-cancer drug" in targeted cancer therapy.
- Aug 2021Series A$5.9M
#6
Seed · Anyang, Gyeonggi do · founded 2008—raised▾
Developer of rapid diagnostic test kits for COVID-19. The company utilizes proprietary surface coating technology to develop lateral flow immunochromatographic assay for detecting nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal swab specimens.
- Nov 2023Seed—
#7
Seed · Gunpo si, Gyeonggi do · founded 2013 · 22 employees—raised▾
Medihub manufactures anesthetic injection systems. The products are I-Ject, I-Ject IN, and I-Ject pro. I-Ject is a wireless digital anesthetic injection system. I-Ject IN dental chair built-in wired digital automatic anesthetic injection system. I-Ject pro is an injector able to inject fixed volume at a constant speed.
- 2018Seed—
#8
Public · Yongin si, Gyeonggi do · founded 2006 · 86 employees—raised▾
Developer of PNA Therapeutics for the treatment of multiple diseases. The company is developing OliPass, a class of oligonucleotides rationally designed to possess good cell permeability as well as a strong affinity for RNA and/or DNA. It claims that this good cell permeability allows the selective modulation of gene functions without relying on invasive formulations to deliver oligonucleotide molecules into the cell. Its pipeline currently has 5 programs targeting the different genes for the indications such as neuropathic pain, diabetes, Alopecia, wrinkles, and muscular dystrophy.
- 2018Seed—
#9
Public · Yongin si, Gyeonggi do · founded 2009 · 26 employees—raised▾
Provider and developer of aptamers based on platform technology. The company uses the systematic evolution of ligands by exponential enrichment (SELEX) technology for the generation of oligonucleotides with a high target affinity. These SELEX-derived single-stranded DNA and RNA molecules, called aptamers, were selected against various targets, such as proteins, cells, microorganisms, chemical compounds - etc. They can be used as novel antibodies, in cancer theranostics, and in biomedical research. Additionally, the company offers Lipofector Q a polycationic liposomal reagent for high-efficiency transfection.
- 2016Series B—
- 2015Series A—
- 2009Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in South Korea
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 885 South Korea-affiliated papers.
- Ministry of Agriculture118
- Ministry of Education70
- Seoul National University53
- Yonsei University44
- Korea University36
- Gene2→26
- Genome1→10
- Transcription factor1→9
- Genome editing1→6
- Transformation (genetics)1→6
- Antimicrobial1→23
- Apoptosis1→12
- Cell culture2→10
- Cytotoxicity2→8
- Gene knockdown1→7
- Human health2→11
- Health benefits1→6
- Antibiotic resistance1→4
- Toxicity2→4
Where biotechnology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in South Korea
South Korea biotechnology patent filing is accelerating — 58,964 filings from 8,000 assignees (2016–2025), led by CJ Cheiljedang, UNIV Korea RES & BUS Found, Samsung; annual filings 4052→6791.
- CJ Cheiljedang6608
- UNIV Korea RES & BUS Found1920
- Samsung1764
- Korea Advanced INST SCI & TECH1756
- Seoul NAT UNIV R&DB Foundation1752
- Korea RES INST Of Bioscience1535
- Hanmi Pharm IND1198
- Korea RES INST Bioscience & Biot1009
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.